Genomics of high-risk myeloma

During COMy 2020, Nikhil Munshi, Dana-Farber Cancer Institute, Boston, US, spoke to the Multiple Myeloma Hub about genomics of high-risk MM.


Here, Nikhil Munshi highlights the positive shift in survival outcomes of patients with high-risk MM in recent years, owing to emerging treatments and diagnostic techniques. Three major points are discussed:

1. Who is high risk?

2. What are the characteristics of high-risk MM?

3. How do we treat patients with high-risk disease?


See acast.com/privacy for privacy and opt-out information.

Om Podcasten

Guided by an international Steering Committee of world experts in Multiple Myeloma (MM), the MM Hub is a global online resource providing key information on Multiple Myeloma for hematologists, oncologists and researchers, run in collaboration with the European School of Haematology (ESH). Our mission is to provide the latest global up-to-date clinical guidance in Multiple Myeloma, through a comprehensive coverage of evidence-based literature, drug approvals, case studies, expert opinions and international congress reports. Hosted on Acast. See acast.com/privacy for more information.